18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients (Q38098441)

28 August 2017

title

18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients (English)

1 reference

28 August 2017

1 reference

Claudia Brogsitter

1

1 reference

28 August 2017

Klaus Zöphel

series ordinal

2

1 reference

28 August 2017

Jörg Kotzerke

series ordinal

3

1 reference

28 August 2017

publication date

12 April 2013

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

28 August 2017

published in

1 reference

28 August 2017

volume

40 Suppl 1

1 reference

28 August 2017

page(s)

S18-27

1 reference

28 August 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

[(18)F]Fluoroacetate is not a functional analogue of [(11)C]acetate in normal physiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Mediastinal lymph node uptake in patients with prostate carcinoma on F18-choline PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Biodistribution and radiation dosimetry of [(11)C]choline: a comparison between rat and human data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Kinetics of [(11)C]choline uptake in prostate cancer: a PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

1-11C-acetate kinetics of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Metabolic alterations and targeted therapies in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

[11C]Choline as a PET biomarker for assessment of prostate cancer tumor models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Effects of irradiation on the [Methyl-3H]choline uptake in the human prostate cancer cell lines LNCaP and PC3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Incidence and clinical significance of false-negative sextant prostate biopsies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Detection of prostate cancer with magnetic resonance imaging: optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coefficient mapping sequences and MR spectroscopy, correlated with bi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Preoperative detection of prostate cancer: a comparison with 11C-choline PET, 18F-fluorodeoxyglucose PET and MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Improved detection of localized prostate cancer using co-registered MRI and 11C-acetate PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Functional imaging of localized prostate cancer aggressiveness using 11C-acetate PET/CT and 1H-MR spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Visualization of prostate cancer with 11C-choline positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

[18F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

[18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

[11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

[18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

[11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

11C/ 18F-choline PET or 11C/18F-acetate PET in prostate cancer: may a choice be recommended?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

[(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

[11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

[(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

[11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

¹⁸F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Predictive factors of [18F]-Choline PET/CT in 170 patients with increasing PSA after primary radical treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2358-2

18F-fluoroacetate: a potential acetate analog for prostate tumor imaging--in vivo evaluation of 18F-fluoroacetate versus 11C-acetate.

21 January 2018

1 reference

12 December 2020

Prospective Evaluation of 11C-Choline Positron Emission Tomography/Computed Tomography and Diffusion-Weighted Magnetic Resonance Imaging for the Nodal Staging of Prostate Cancer with a High Risk of Lymph Node Metastases

1 reference

12 December 2020

Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer

1 reference

12 December 2020

Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET.

1 reference

12 December 2020

11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse

1 reference

12 December 2020

Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy

1 reference

12 December 2020

Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading.

1 reference

12 December 2020

Radiation dose estimates in humans for (11)C-acetate whole-body PET.

1 reference

12 December 2020

Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence.

1 reference

12 December 2020

Pharmacokinetics and radiation dosimetry of 18F-fluorocholine.

1 reference

12 December 2020

Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy

1 reference

12 December 2020

Influence of 11C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer

1 reference

12 December 2020

PET imaging of prostate cancer using carbon-11-choline.

1 reference

12 December 2020

Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer

1 reference

12 December 2020

PET for prostate cancer imaging: still a quandary or the ultimate solution?

1 reference

12 December 2020

Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer

1 reference

12 December 2020

11C-acetate PET imaging of prostate cancer.

1 reference

12 December 2020

Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis

1 reference

12 December 2020

Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis

1 reference

12 December 2020

10.1007/S00259-013-2358-2

Identifiers

DOI

1 reference

28 August 2017

1 reference